MILLENNIUM PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2014-03-03
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01179399
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT01177228
Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
Phase 1
Terminated
- Conditions
- Prostate CancerProstatic Neoplasms
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01132404
- Locations
- 🇫🇷
Hôpital Edouard Herriot, 5, Place d'Arsonval, Pavillon V - Urologie et chirurgie de la transplantation, Lyon, France
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Phase 1
Completed
- Conditions
- Relapsed Multiple MyelomaRefractory Multiple MyelomaWaldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01118689
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Phase 1
Completed
- Conditions
- Advanced Solid TumorsAdenocarcinoma of the Prostate
- Interventions
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01094288
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Phase 2
Completed
- Conditions
- Ovarian CarcinomaBreast CarcinomaFallopian Tube CancerPeritoneal Cancer
- Interventions
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 191
- Registration Number
- NCT01091428
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01084655
- Locations
- 🇺🇸
Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT01058707
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01046916
- Locations
- 🇺🇸
Oregon Health and Sciences University, Portland, Oregon, United States
🇺🇸University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Phase 1
Completed
- Conditions
- Advanced Nonhematological MalignanciesMetastatic Breast CancerSmall Cell Lung CancerGastroesophageal AdenocarcinomaHead and Neck Squamous Cell CarcinomaNon-Small Cell Lung Cancer
- Interventions
- Drug: MLN8237 (Alisertib)
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 273
- Registration Number
- NCT01045421
© Copyright 2025. All Rights Reserved by MedPath